Eliminating side effects by manipulating molecular chirality

Friday, 19 June, 2020

Eliminating side effects by manipulating molecular chirality

Scientists from Hong Kong Baptist University (HKBU) have developed a novel technique that can produce pure therapeutic drugs without the associated side effects.

The approach uses a nanostructure fabrication device to manipulate the chirality of drug molecules by controlling the direction in which a substrate is rotated within the device, thus eliminating the possible side effects that can arise when people take drugs containing molecules with the incorrect chirality. Published in the journal Nature Chemistry, the research paves the way towards the mass production of purer, cheaper and safer drugs that can be made in a scalable and more environmentally friendly way.

Control of molecular chirality improves drug safety

Many chemical molecules have two configurations, or chiral versions, that are mirror images of each other. While sharing the same molecular formula, the two chiral versions have different arrangements of their constituent atoms in space. The two versions of the molecules are characterised by ‘left-handed’ and ‘right-handed’ chiral configurations like human hands; molecules with left-handed and right-handed chirality can have totally different biochemical effects.

More than half of the therapeutic drugs are made up of equal amounts of left-handed and right-handed chiral molecules, commonly known as ‘racemates’; one can cure specific diseases, but the other may have adverse effects. Separating and producing molecules with only the chiral arrangement (known as a single enantiomer) responsible for the therapeutic effects can help to produce drugs with improved safety and efficacy.

Macroscale control of molecular chirality

In general, molecules have an extremely small size ranging from one-millionth to one-hundred-thousandth of the diameter of a human hair. It is therefore extremely challenging to selectively produce one of the two chiral molecule versions using macroscale control, ie, the dimensional scale that can be seen using the naked eye and operated by hand. To produce single-enantiomer drugs, chemists have overwhelmingly used molecules called ‘chiral ligands’ to effectively control the molecular chirality of drugs in the laboratory or industry at the molecular scale, a process called asymmetric synthesis. However, the existing technologies for producing single-enantiomer drugs are composed of complicated procedures, which are expensive and environmentally unfriendly.

HKBU’s Dr Jeffery Huang Zhifeng and his research team devised a novel approach to manipulating molecular chirality through macroscale control in collaboration with Sichuan University, Guangxi Medical University and the Southern University of Science and Technology. This involves mediating the manipulation with helical metal nanostructures (ie, metal nanohelices) that are in the shape of a helical spring, and they have a characteristic size of one-thousandth of the diameter of a human hair.

Direction of rotation determines molecular chirality

The research team fabricated the metal nanohelices using a nanofabrication technique called glancing angle deposition (GLAD). Silver and copper were deposited onto a supporting substrate that was rotated clockwise and anticlockwise to fabricate the right-handed and left-handed metal nanohelices, respectively.

The research team then used ultraviolet light to induce a chemical reaction. This caused 2-anthracenecarboxylic acid (AC) molecules adsorbing on the metal nanohelices to undergo the chemical reaction and form chiral molecular products, which are similar to some chiral drugs. When AC was attached to the surface of the right-handed metal nanohelices and exposed to ultraviolet light, it preferentially produced right-handed chiral molecular products. By the same token, when AC was adsorbed on the surface of the left-handed metal nanohelices and exposed to ultraviolet light, it preferentially produced left-handed chiral molecular products. In other words, the chirality of the molecular product can be reliably determined by the chirality of the metal nanohelices, which is controlled by the direction of substrate rotation.

The research demonstrates that controlling the direction of substrate rotation at a macroscopic level can conveniently manipulate molecular chirality. This is said to be an unprecedented application of the macroscale method (through the control of the rotation direction of a 10 cm substrate holder) to manipulate chirality at the molecular-scale (chiral molecular products in the range of one-billionth of a metre).

Green approach to reducing drug side effects

“Our success in manipulating molecular chirality through macroscopic engineering allows the convenient synthesis of drugs in single-enantiomer forms with only left- or right-handedness. Hence, it will help get rid of the adverse, sometimes fatal, side effects of many therapeutic drugs,” Dr Huang said.

The use of chiral ligands in the conventional method of asymmetric synthesis is inevitable, and it may cause pollution to enter the environment. In contrast, in this novel approach the metal nanohelices can be used repeatedly to produce single-enantiomer drugs without the use of chiral ligands. As a result, it paves the way towards the mass production of affordable therapeutic drugs that are made in a scalable manner with recyclable materials.

Image caption: Dr Jeffery Huang Zhifeng has developed a novel approach to manipulating the chirality of drug molecules.

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related Articles

8 myths about mRNA COVID-19 vaccines explained

Dr Thaddeus Stappenbeck dispels fears about the new generation of vaccines and explains that they...

Drug inhibits cancer cell growth by attacking mitochondria

A newly developed compound starves cancer cells by attacking their 'power plants', by...

Oral insulin nanoparticles could replace injections

Scientists have developed insulin nanoparticles that may one day become the basis for an oral...

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd